Vertex to submit VX-445, Tezacaftor and Ivacaftor regimen for global regulatory approvals in cystic fibrosis
Final data announced today from a 24-week Phase 3 study in people with one F508del mutation and one minimal function mutation and from a 4-week Phase 3 study